Accurate accounting of relapses is critical for MS trials, but they are often under-detected.
Objective:
To evaluate whether scheduled check-ins with trial participants improve relapse capture.
Methods:
In 165 VIDAMS trial participants, we evaluated whether systematic between-visit contact in which coordinators asked specific questions about symptoms were temporally associated with detection of relapses.
Results:
The odds of detecting confirmed relapse in the 2 weeks after, versus the 2 weeks before, scheduled contact with coordinators were almost 3-fold higher (odds ratio (OR) = 2.93, 95% confidence interval (CI) = 1.3–6.60, p = 0.01).
Conclusions:
Systematic symptom screening between study visits may improve relapse detection in MS trials.
Van MunsterCEPUitdehaagBMJ. Outcome measures in clinical trials for multiple sclerosis. CNS Drugs2017; 31(3): 217–236.
2.
McDonaldWICompstonAEdanG, et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol2001; 50(1): 121–127.
3.
LindseyJScottTLynchS, et al. The CombiRx trial of combined therapy with interferon and glatiramer acetate in relapsing remitting MS: Design and baseline characteristics. Mult Scler Relat Disord2012; 1(2): 81–86.
4.
StoppeMBuschMKrizekL, et al. Outcome of MS relapses in the era of disease-modifying therapy. BMC Neurol2017; 17(1): 151.
5.
NazarethTARavaARPolyakovJL, et al. Relapse prevalence, symptoms, and health care engagement: Patient insights from the multiple sclerosis in America 2017 survey. Mult Scler Relat Disord2018; 26: 219–234.
6.
WaltripRWMahlerNAhsanA, et al. Effect of health care providers’ focused discussion and proactive education about relapse management on patient reporting of multiple sclerosis relapse. Int J MS Care2021; 23(4): 151–156.
7.
LublinFDCofieldSSCutterGR, et al. Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Ann Neurol2013; 73(3): 327–340.
8.
CassardSDFitzgeraldKCQianP, et al. High-dose vitamin D3 supplementation in relapsing-remitting multiple sclerosis: A randomised clinical trial. EClinicalMedicine2023; 59: 101957.
9.
FoxRJMehtaRPhamT, et al. Real-world disease-modifying therapy pathways from administrative claims data in patients with multiple sclerosis. BMC Neurol2022; 22(1): 211.
10.
HendersonMHortonDBBhiseV, et al. Initiation patterns of disease-modifying therapies for multiple sclerosis among US adults and children, 2001 through 2020. JAMA Neurol2023; 80(8): 860–867.
